Literature DB >> 19141525

Effect of linezolid compared with glycopeptides in methicillin-resistant Staphylococcus aureus severe pneumonia in piglets.

Carlos M Luna1, Didier A Bruno2, Joaquín García-Morato3, Keli C Mann4, Juan Risso Patrón2, Judith Sagardía3, Rubén Absi5, Milagros García Bottino5, Diana Marchetti5, Angela Famiglietti5, Mónica Baleztena6, Cesar Biancolini3.   

Abstract

OBJECTIVES: To investigate if compared with glycopeptides, antimicrobial therapy (AMT) with linezolid (LZD) improves the outcome in methicillin-resistant Staphylococcus aureus (MRSA) experimental pneumonia in mechanically ventilated piglets.
METHODS: The MRSA minimal inhibitory concentration (MIC) was 0.5 for vancomycin (VAN), 0.25 for teicoplanin (TEI), and 2.0 microg/mL for LZD was inoculated in Largewhite-Landrace piglets divided into five groups. One group (n = 6) did not receive mechanical ventilation (MV) or AMT. Those in the remaining groups received MV and VAN (n = 9), TEI (n = 7), LZD (n = 9), or no AMT (n = 7). Plasma and BAL tumor necrosis factor-alpha, interleukin-6, and C-reactive protein (CRP) concentrations, postmortem lung pathology, cultures (lung, blood, and BAL) and plasma, epithelial lining fluid (ELF), and lung antibiotic concentrations were evaluated.
MEASUREMENTS AND MAIN RESULTS: All piglets developed severe pneumonia; lung pathology score was lower in those receiving LZD vs those receiving glycopeptides (p = 0.049) or no AMT (p = 0.037). Serum CRP and serum and BAL cytokines increased; there were no differences between the groups. Fourteen died spontaneously at 44.4 +/- 16.8 h; the remaining 24 were killed after 72 to 96 h. The concentrations of the antimicrobial agents tested in 15 piglets were higher than the MIC for the three antimicrobial agents in peak and trough plasma, ELF, and lung specimens. Survival at 72 h was higher in the LZD comparing with the no-AMT group.
CONCLUSIONS: Inoculation produced severe MRSA pneumonia. LZD AMT was associated with lower pathology score, better survival, and a trend to better clearance of MRSA, not attributable exclusively to pharmacokinetic or pharmacodynamic reasons.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19141525     DOI: 10.1378/chest.08-2169

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  8 in total

1.  Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials.

Authors:  Allan J Walkey; Max R O'Donnell; Renda Soylemez Wiener
Journal:  Chest       Date:  2010-09-23       Impact factor: 9.410

Review 2.  Does animal model on ventilator-associated pneumonia reflect physiopathology of sepsis mechanisms in humans?

Authors:  Laura Pulido; Diego Burgos; Joaquín García Morato; Carlos M Luna
Journal:  Ann Transl Med       Date:  2017-11

Review 3.  The Role of Antibiotics in Modulating Virulence in Staphylococcus aureus.

Authors:  Elisabeth Hodille; Warren Rose; Binh An Diep; Sylvain Goutelle; Gerard Lina; Oana Dumitrescu
Journal:  Clin Microbiol Rev       Date:  2017-10       Impact factor: 26.132

4.  Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model.

Authors:  Alexander J Lepak; Karen Marchillo; Solen Pichereau; William A Craig; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2012-09-10       Impact factor: 5.191

Review 5.  Clinical Pharmacokinetics and Pharmacodynamics of Oxazolidinones.

Authors:  Claire Roger; Jason A Roberts; Laurent Muller
Journal:  Clin Pharmacokinet       Date:  2018-05       Impact factor: 6.447

Review 6.  Linezolid effects on bacterial toxin production and host immune response: review of the evidence.

Authors:  Binh An Diep; Ozlem Equils; David B Huang; Ron Gladue
Journal:  Curr Ther Res Clin Exp       Date:  2012-06

Review 7.  Linezolid and Its Immunomodulatory Effect: In Vitro and In Vivo Evidence.

Authors:  Jin Wang; Lei Xia; Rui Wang; Yun Cai
Journal:  Front Pharmacol       Date:  2019-11-28       Impact factor: 5.810

Review 8.  Teicoplanin-A New Use for an Old Drug in the COVID-19 Era?

Authors:  Vladimir Vimberg
Journal:  Pharmaceuticals (Basel)       Date:  2021-11-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.